Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaTcH Trial
2024-513429-21-00Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib and hydroxychloroquine in pancreatic adenocarcinoma (PDAC), sponsored by Cancer Trials Ireland. Primary endpoint: 12-week progression-free survival. Started Jun 2024; status: completed.
02
Drugs
trametinibhydroxychloroquine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-513429-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513429-21-00.